When Paul, Weiss, Rifkind, Wharton & Garrison partner Nicholas Groombridge appears at the U.S. Court of Appeals for the Federal Circuit for Amgen Inc. next week, he may present one of the most expensive appeals of his life.
Amgen’s opponent, Sandoz Inc., has asked the Federal Circuit to impose a $460,000 bond—per day—over the life of the appeal. That’s because Sandoz was set to begin marketing a biosimilar version of Amgen’s bone marrow stimulant Neupogen before the Federal Circuit enjoined Sandoz on May 5 pending appeal.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
